Induction of phenotypically determined resistance of Neisseria gonorrhoeae to human serum by sera from patients with gonorrhoea

P M V Martin, P V Patel, N J Parsons, and H Smith

From the Department of Microbiology, University of Birmingham, Birmingham

SUMMARY Some human sera contain factors which induce in gonococci a resistance to killing by fresh human sera. Individuals with serum containing these factors might possibly be more prone to gonorrhoea. A survey of the sera of 50 female and 50 male patients with gonorrhoea for resistance-inducing capacity showed, however, that the proportions of positive sera (24% for women, 28% for men) were not significantly different from those (16% for women, 24% for men) from an equal number of controls. Examination of the results, however, in relation to the type of gonococcal infection showed that: (a) the sera of 15 female patients with complicated (salpingitis) or successive infection or both did not induce resistance (statistically significant); (b) a greater proportion (34%) of sera from female patients with single gonococcal infections induced higher gonococcal resistance than for control sera (16%) (at the borderline of statistical significance); and (c) a greater proportion (38%) of sera from the few male patients with successive infections induced higher resistance than for control sera (24%) (not statistically significant).

Introduction

The resistance of Neisseria gonorrhoeae to killing by normal human serum, considered to be an important factor in pathogenesis,¹ is of two different types. The first type is retained after several subcultures of the organisms in vitro and concerns most strains isolated from disseminated gonococcal infection.² The second type concerns mainly strains isolated from acute urogenital infections in men or women and is phenotypically determined; it is exhibited by gonococci grown in vivo (that is, from urethral exudate) but is lost after subculture in normal laboratory media.³ Recently, the latter type of resistance has been induced in a synthetic medium in vitro by guinea pig sera⁴ and by a proportion (about 25%) of sera taken from healthy human donors.⁵ With a positive serum, conversion of a serum-sensitive strain to serum resistance occurred in three hours at 37°C and better at a slightly acid pH.⁶ The inducing capacity of serum was increased by freezing and thawing and was due to factors of both high and low molecular weights.⁷

The possible importance of the resistance-inducing factor in the pathogenesis of gonorrhoea was further emphasised by the recent finding that vaginocervical secretions and seminal plasmas have a resistance-inducing activity as shown by some human sera.⁸ Individuals who form the resistance-inducing factors might, therefore, possibly be more prone to gonorrhoea than those in whom the factors could not be detected. Hence, the resistance capacities of sera from 100 patients (50 men and 50 women) were compared with those of sera from 100 controls.

Materials and methods

SERAS

The sera of 100 patients (50 women and 50 men) attending the venereal disease clinic of the Birmingham General Hospital were examined in 1981 by the courtesy of Dr J F Clay. In all patients gonorrhoea was diagnosed by microscopy of stained smears and culture for N gonorrhoeae. Some patients had a previous history of gonorrhoea and others had complications of infection, for example, salpingitis. Blood (10 ml) was collected by venous puncture before treatment and clotted at room temperature for 1-2 hours. After standing at 4°C for 48 hours the sera were separated and heat-inactivated (at 56°C for 40 minutes).
As controls, blood samples from 100 healthy donors (50 women and 50 men of similar age range as the patients) of the National Blood Transfusion Service, Birmingham, were similarly heated and in parallel. All sera from patients and controls were screened for hepatitis agents before use.

The sera were tested for resistance-inducing activity before and after one, three, and sometimes four freezings (at −20°C) and thawings (at 37°C). 5

**SERUM-SENSITIVE NEISSERIA GONORRHOEAE**

This was strain BS4 (agar) derived, stored, and cultured as described. 7

Viable counts and defined medium (DM) were as described. 8 9

**GENERATION OF RESISTANT ORGANISMS.**

This was performed as described. 9 The medium (100 μl) consisted of a 1/1 mixture of DM and serum at a final pH of 6.4-6.6. Serum-sensitive gonococci (5 × 10⁴/ml in 10 μl of DM) were added in the wells of microtitre plates (Flow laboratories, Irvine, Scotland) and incubated for three hours at 37°C. Estimates of growth were made by plating out duplicates (10 μl) of the mixture before and after incubation.

Serum resistance was measured as described. 9 The number of colony forming units (cfu) recovered after incubation of the above suspension of organisms (0·5-1·0 × 10⁶ organisms) for 40 minutes at 37°C with fresh human serum (FHS) was given as a percentage of units obtained when heat-inactivated serum (56°C for 60 minutes) was used.

**Results**

The sera were tested before and after freezing and thawing and the results confirmed the increase in resistance-inducing activity which has been noted before. 5 Thus, the mean percentages of strain BS4 (agar) rendered serum-resistant in the standard procedure by sera that were examined before freezing and thawing and after one and three (or four) freezings and thawings were: 20, 23, and 22 for the 50 female patients respectively; 7, 18, and 15 for the 50 female controls respectively; 17, 20, and 32 for the 50 male patients respectively; and 13, 22, and 36 for the 50 male controls respectively. The figures in table I were derived from one value for percentage conversion by each serum; this was the highest percentage recorded, usually after the third (or fourth) freeze-thawing but sometimes after the first.

Table I shows that the proportion of sera inducing serum resistance to more than 50% of the gonococci was 24% for female patients compared with 16% for the controls and 28% for the male patients compared with 25% for the controls. The differences were not significant but a more detailed examination showed some interesting trends.

None of the seven female patients with complicated infections had sera which induced resistance and only two of 11 female patients with a previous history of infection had active sera and then at a very low level. There was no significant difference between the results of the sera of either of these two subdivisions of the female patients and those of the sera of the remaining patients with gonorrhoea. If the results of the sera from female patients with either complicated or repeat infections are combined, however, and viewed with respect to their ability to induce serum resistance to more than 50% of the standard inoculum (table II; three patients had both repeat infections and salpingitis), a significant difference was present between them (group 2, table II) and those of the sera of female patients with a first episode of uncomplicated gonorrhoea (group 1) (χ² test with Yates's correction, χ²<0.05). Furthermore, when the proportion of sera of group 1 inducing serum resistance to more than 50% of the gonococci (34% of a total of 35 sera, table II) were

**TABLE I** Ability of sera from patients with gonorrhoea and controls to induce serum resistance in Neisseria gonorrhoeae

<table>
<thead>
<tr>
<th>Origin of sera</th>
<th>Total No</th>
<th>0-20</th>
<th>21-50</th>
<th>51-80</th>
<th>&gt;80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female patients</td>
<td>50</td>
<td>33</td>
<td>5</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>With previous history</td>
<td>11</td>
<td>9</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>With complications</td>
<td>7</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Female controls</td>
<td>50</td>
<td>38</td>
<td>4</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Male patients</td>
<td>50</td>
<td>25</td>
<td>11</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>With previous history</td>
<td>13</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Male controls</td>
<td>50</td>
<td>21</td>
<td>17</td>
<td>4</td>
<td>8</td>
</tr>
</tbody>
</table>

*Of gonorrhoea
†For example, salpingitis

**TABLE II** Ability of sera from female patients without or with complicated or repeat gonococcal infection or both to induce resistance in Neisseria gonorrhoeae compared with healthy controls

<table>
<thead>
<tr>
<th>Origin of sera</th>
<th>Total No</th>
<th>0-50</th>
<th>51-100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female controls</td>
<td>50</td>
<td>42</td>
<td>8</td>
</tr>
<tr>
<td>Female patients</td>
<td>35</td>
<td>23</td>
<td>12</td>
</tr>
<tr>
<td>Group 1*</td>
<td>15</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Group 2†</td>
<td>15</td>
<td>15</td>
<td>0</td>
</tr>
</tbody>
</table>

*With first uncomplicated episode of gonorrhoea
†With either complicated (salpingitis) or repeat gonococcal infection
compared with the corresponding proportion of control sera (16% of a total of 50) the proportion for the sera from the patients with gonorrhoea was on the borderline of being significantly greater ($\chi^2 = 3.78$, $P<0.052$; $\chi^2 = 3.84$, $P<0.05$) than that for the control sera. For the sera from the male patients, the proportion of sera inducing serum resistance to more than 50% of the gonococci was 24% (of a total of 37) for patients with single infections and 38% (of a total of 13) for the sera of patients with repeat infections. Although this figure was higher than that for the control sera (24% of 50 sera) it was not statistically significant because of the small numbers involved.

The blood grouping of 67 female patients and controls were known but no correlations could be drawn between induction of serum resistance and A, B, O, or rhesus blood grouping.

**Discussion**

At first sight the results of this survey were disappointing in terms of a possible relation between the presence of the inducing factor in serum and ease or severity of the gonococcal infection. There was no significant difference between the overall results of the sera of female patients, female controls, male patients, and male controls. However, some interesting trends came from a closer examination in relation to the type of gonococcal infection suffered by the patients.

First, the sera of the few female patients with complicated gonococcal infections (notably salpingitis) and of the small number with a previous history of gonococcal infection showed a conspicuous lack of resistance-inducing activity. When the results of the sera from patients with complicated or successive gonococcal infection or both were combined and compared with those of the sera of patients with uncomplicated infection (Table II), a significant difference ($P<0.05$) emerged, indicating an inverse relationship between severity and repeated infection and the presence of the resistance-inducing factors. This inverse relationship may indicate that the absence of the gonococcal surface determinant of phenotypic serum resistance in these patients allows other determinants of pathogenicity, such as those causing inhibition of ingestion or killing of gonococci by phagocytes, to operate more freely leading to increased invasion of the host.

Second, when the sera of infected female patients with neither uncomplicated nor repetitive infection were viewed alone and compared with the control sera, the proportion of sera inducing high gonococcal resistance was greater for the sera of the infected patients. Here there was a suggestion of a relation between the presence of the inducing factor and ease of infection. Another along the same lines but more tenuous because of the small numbers of samples involved was the fact that the sera of male patients with repeated infection contained a higher proportion of samples inducing high gonococcal resistance than the sera of controls.

These interesting trends warrant further comparisons with larger numbers of sera from female and male patients whose type of gonococcal infections are known.

The authors wish to thank Mr Loeb and the technical staff of the National Blood Transfusion Service, Birmingham, for their helpful assistance in screening sera for hepatitis agents.

**References**